Chinese biotech firm offers unproven iPS cell treatment

08/5/2008 | InformationWeek

China-based Beike Biotechnology is using a promising but untested therapy involving induced pluripotent stem cells to treat hundreds of patients -- many from Western countries -- suffering from diseases deemed incurable, such as cerebral palsy and muscular dystrophy. The company's technology, which uses a combination of umbilical-cord cells and stem cells extracted from patients, "may someday create the conditions for effective clinical treatments and industrial scale production of iPS cells," a U.S. researcher said.

View Full Article in:

InformationWeek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Director, Quality Regulatory Affairs
Cardinal Health
Chicago, IL
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC